Cystinuria Epidemiology Forecast 2025-2034

Cystinuria is identified as the most common inheritable cause of kidney stones. The incidence of cystinuria is estimated to be around 1 in 7,000 population worldwide, as well as in the United States. Cystinuria epidemiology forecast indicates that the condition is more prevalent in men, with the male-to-female ratio reported to be 2:1.

Cystinuria Epidemiology Forecast Report Coverage

The “Cystinuria Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of cystinuria. It projects the future incidence and prevalence rates of cystinuria cases across various populations. The study covers age, gender, and type as major determinants of the cystinuria population. The report highlights patterns in the prevalence of cystinuria over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on cystinuria epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Cystinuria Understanding: Disease Overview

Cystinuria refers to a rare, inherited condition that causes the accumulation of cystine (an amino acid) in the urine. The condition is characterized by the formation of cystine stones in the ureters, kidneys, and bladder due to the inability of the kidneys to properly reabsorb cystine back into the bloodstream. Common symptoms include hematuria (blood in the urine), flank pain, loin pain, fever (particularly during kidney stone episodes), and vomiting, among others.

Cystinuria Epidemiology Perspective

The cystinuria epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for cystinuria epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cystinuria and their trends. The cystinuria detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The estimated global prevalence of cystinuria is about 1:7,000, as per the Orphanet.
• Around 20% to 40% of cystinuria patients experience additional kidney stone-related urinary chemical abnormalities, including hypocitraturia (44%), hypercalciuria (19%), or hyperuricosuria (22%).
• The M467T mutation in the SLC3A1 gene (linked to cystinuria), prevalent in individuals of Mediterranean origin, accounts for nearly 50% of cases in Spain but is rare globally.

Age-Based Cystinuria Epidemiology Insights

Cystinuria can develop at any age, but kidney stones typically begin to form during the first 20 years of life. The average age for the onset of symptoms, such as renal colic due to cystine stones, is around 15 years. However, it is estimated that approximately 22% of individuals with cystinuria will start developing kidney stones during childhood.

Gender-Based Cystinuria Epidemiology Insights

Males tend to have more severe cystinuria cases, with kidney stones often occurring before age 3. The male-to-female ratio is reported to be 2:1. Over 75% of cases involve bilateral stones, and the recurrence rate is higher in males, exceeding 60%, according to Orphanet. However, renal insufficiency is rare in both genders.

Country-wise Cystinuria Epidemiology Segment

The cystinuria epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cystinuria varies between countries, owing to differences in factors such as genetic predisposition, environmental influences, dietary habits, and healthcare infrastructure, among others. In the United States, cystinuria is estimated to occur in about 1 in 7,000 to 10,000 individuals

Cystinuria: Treatment Overview

Lifestyle and dietary changes, such as increased fluid intake, reduced intake of animal protein, and restriction of dietary sodium, are usually the first line of treatment. Cystine-binding thiol drugs like tiopronin (alpha-mercaptopropionylglycine) and D-penicillamine are prescribed if conservative measures are not effective. These cystinuria therapeutics work by binding to cystine in the urine to form a more soluble complex that can be easily excreted.

Key Questions Answered

• What are the key findings of cystinuria epidemiology in the 8 major markets?
• What will be the total number of patients with cystinuria across the 8 major markets during the forecast period?
• What was the country-wise cystinuria epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cystinuria patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cystinuria during the forecast period of 2025-2034?
• What are the currently available treatments in the cystinuria market?
• What are the disease risks, signs, symptoms, and unmet needs of cystinuria?

Scope of the Cystinuria Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cystinuria based on several factors.
• Cystinuria Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The cystinuria report helps to identify the patient population and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.